Monogram Announces Issuance of Key Patents Related to VeraTag(TM) Technology
July 23 2008 - 6:00AM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ --
Monogram Biosciences, Inc. (NASDAQ:MGRM) announced today that three
key United States Patents for its proprietary VeraTag(TM)
technology have been issued (United States Patent numbers
7,402,397; 7,402,398 and 7,402,399). The patents are broad and
relate to the use of Monogram's VeraTag technology for methods of
detecting and profiling protein complexes, including protein
homodimers and heterodimers. A European Patent (number 1278760) has
also been issued in respect of these claims. Being able to detect
and profile protein complexes is important because proteins achieve
their biological function when they interact, form protein
complexes and thereby trigger cellular signaling processes. In this
way, protein complexes are pivotal in regulating cellular survival
and proliferation in normal and cancer cells. Examples of protein
complexes are those involving the same proteins pairing up to form
"homodimers" and different proteins pairing up to form
"heterodimers." Being able to detect and profile normal and
aberrant protein complexes, such as homodimers and heterodimers, is
believed to be important for predicting patient prognosis and
response to therapy. The issued patent claims around the methods of
profiling and detecting protein complexes are broad and cover all
types of protein complexes, including homodimers and heterodimers,
detected with the VeraTag method. Examples of protein complexes
covered by the patents include complexes involving the ErbB (or
HER) proteins, such as EFGR (or HER1), HER2, HER3, as well as
Vascular Endothelial Growth Factor receptors, such as VEGFR2, and
G-protein coupled receptors. Other such proteins include PI3
Kinase, Grb2, SOS, Ras, Raf, IGF1-R, the platelet derived growth
factor receptors and AKT and most proteins involved in signal
transduction. "The latest issued patents provide patent protection
for some of the most important applications of our VeraTag
technology -- those related to the identification of protein
complexes," said William D. Young, Monogram's Chief Executive
Officer. "We believe that determining the status of particular
protein complexes, such as homodimers and heterodimers, will be
important for determining whether a patient's tumor will respond to
certain drugs." "Protein complexes are considered to be critical to
the mechanisms of action of many cancer drugs," said Gordon Parry,
Ph.D., Monogram's Vice President of Oncology Research and
Development. "Yet, until now, they have not been readily measurable
in tumor samples, in particular in formalin-fixed paraffin-embedded
(FFPE) samples. Our VeraTag technology is changing that, enabling
accurate and quantitative measurements of protein complexes not
previously possible. This is a unique advantage of the VeraTag
platform and the patent protection achieved today is very
important." Monogram's worldwide patent portfolio includes 78
issued and pending patents and patent applications related to its
VeraTag technology, 102 issued and pending patents and patent
applications related to its virology technology and 101 issued and
pending patents and patent applications related to its
microfluidics technology. Monogram's corporate patent portfolio has
recently been ranked as one of the pre-eminent biotechnology
portfolios in the country based on science strength and commercial
fit according to the Patent Board in its annual Biotechnology
Patent Scorecard. About Monogram Monogram is advancing
individualized medicine by discovering, developing and marketing
innovative products to guide and improve treatment of serious
infectious diseases and cancer. The Company's products are designed
to help doctors optimize treatment regimens for their patients that
lead to better outcomes and reduced costs. The Company's technology
is also being used by numerous biopharmaceutical companies to
develop new and improved antiviral therapeutics and vaccines as
well as targeted cancer therapeutics. More information about the
Company and its technology can be found on its web site at
http://www.monogrambio.com/. Forward Looking Statements Certain
statements in this press release are forward-looking. These
forward-looking statements include references to importance of
protein measurements to the prediction of response to certain
cancer therapies and successful development and commercialization
of VeraTag assays. These forward-looking statements are subject to
risks and uncertainties and other factors, which may cause actual
results to differ materially from the anticipated results or other
expectations expressed in such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks and
uncertainties relating to the performance of our products the risk
that we may not be able to obtain additional cohorts of patient
samples for additional VeraTag development and studies; actual
market acceptance of our products for patient use and adoption of
our technological approach and products by pharmaceutical and
biotechnology companies; whether the FDA or any other agency will
decide to further regulate our products or services; the ultimate
validity and enforceability of our patent applications and patents;
the possible infringement of the intellectual property of others
and whether licenses to third party technology will be available.
For a discussion of other factors that may cause actual events to
differ from those projected, please refer to our most recent annual
report on Form 10-K and quarterly reports on Form 10-Q, as well as
other subsequent filings with the Securities and Exchange
Commission. We do not undertake, and specifically disclaim any
obligation, to revise any forward-looking statements to reflect the
occurrence of anticipated or unanticipated events or circumstances
after the date of such statements. VeraTag is trademark of Monogram
Biosciences, Inc. Contacts: Alfred G. Merriweather Jeremiah Hall
Chief Financial Officer Feinstein Kean Healthcare Tel: 650 624 4576
Tel: 415 677-2700 amerriweather@ jeremiah.hall@ monogrambio.com
fkhealth.com DATASOURCE: Monogram Biosciences, Inc. CONTACT: Alfred
G. Merriweather, Chief Financial Officer of Monogram Biosciences,
Inc., +1-650-624-4576, , or Jeremiah Hall of Feinstein Kean
Healthcare, +1-415-677-2700, , for Monogram Biosciences, Inc.
Copyright
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jul 2023 to Jul 2024